Main Page - Latest News

online casino

IL government orders taxpayers to provide inmates with $84,000 prescriptions for Hepatitis C

Sovaldi will wreck American health care with its $84k price tag. Even though the same prescription is sold in Egypt for $900.

About 3.2 million Americans have chronic infections from Hepatitis C. Over half caught it from sharing needles. Much of the rest get it from anal sex. A small percentage contract the disease from living in close quarters with an infected person.

About 3,750 inmates in the Illinois Department of Corrections have it. The state currently spends $8 million per year on drugs to treat inmates for the disease. Now the government of Illinois has approved the use of a new drug from Giliad for treating Hepatitis C among it’s prison population. The drug cost $1,000 per daily treatment. A total of $84,000 for the full treatment. The full $84k treatment is supposed to cure 95% of patients. It is predicted that the cost of treating IL inmates will soar to a minimum of $61 million per year.

US taxpayers could end up forced to pay for the drug for nearly two million people around the country. Since the majority of these people got it from sharing needles, a disproportionate amount are on welfare and get free health care through medicaid. A disproportionate amount are also in jail or uninsured.

Gilead has already seen it stock price explode over the introduction of the new drug. However, the price appears to be a total scam. Gilead is charging completely different prices in different countries.

In American, a full treatment cost $84k. In Britain it cost $57k. In Egypt it cost $900. Yes, they are selling the same drug that they charge $1,000 a day in the USA for $10 a day in Egypt.

About $260 Billion is spent on prescription drugs in the USA each year. If all 3.2 million Americans with chronic infections received the $84k treatment, then it would DOUBLE that amount for one year. The Federal government would have to borrow much of that for everyone who would get a free treatment. Despite the steady stream of propaganda fed to the American public, people on welfare and in prison are getting better health care than America’s middle class.

The rest would be paid for by insurance companies. Every single person in the United States, who pays for health insurance, would see their premium rise significantly. Insurances companies are already sounding the alarms and demanding a congressional investigation.


Corrections officials estimate that as many as 3,750 prisoners in the state have hepatitis C, a life-threatening blood-borne infection that’s linked to tainted needles. Chronic hepatitis C, often called a “silent disease,” causes cirrhosis and often requires a liver transplant. Illinois routinely screens inmates for hepatitis C when they are admitted to prison, unless they refuse.

The local newspaper reports Sovaldi will cost state taxpayers $61 million if only one third of prisoners with hepatitis C receive the drug, compared with current treatment costs of $8 million.

John Maki of the John Howard Association, a prison watchdog group in Chicago, says the state is obligated to provide treatment. He noted that undiagnosed inmates could spread the disease to other prisoners or the public once they’re released.

Since Sovaldi earned approval from the Food and Drug Administration in December, controversy about its cost has overshadowed its purported miraculous efficacy.

The potential burden on taxpayers extends beyond jail cells, since more than half of individuals with hepatitis C are veterans, prisoners, the uninsured or Medicaid beneficiaries, according to the New York Times. In all of those cases taxpayers are likely to be saddled with the cost of the medication.

Earlier this year, members of the House Energy and Commerce Committee requested that Gilead Sciences, the maker of the drug, provide explanation for its high price tag. Executives of the company have vowed to meet with members of Congress to address how the company can be sure Sovaldi reaches those who need it most.

CBS News reported earlier this month that stock shares for Gilead Sciences have soared 53 percent over the last year. Sovaldi may generate the biggest sales ever for a drug’s first year, which could bring in as much as $10 billion this year alone, some analysts say.